
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.
Sales increased by 13% in Danish kroner and 18% at CER, driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 8% to 38.37 billion Danish kroner, and Obesity care sales increased by 53% to 20.37 billion Danish kroner.